Orchid Pharma

Big Pharma is vacating infectious diseases research to chase more lucrative segments like oncology and diabetes. This has left behind a gaping void. A set of Indian companies are diving in—Wockhardt, Orchid Pharma and Bugworks. A successful antibiotic drug can change their fortunes.

Q4 results on May 26: GIC, Vadilal Industries, Aurobindo Pharma, Sumitomo Chemical, Nazara Technologies, and Blue Dart are among 205 companies to release their earnings report today.

Here’s a quick look at stocks likely to be in focus in today's trade.

Here are a few stocks likely to be in focus on Tuesday, August 13:

Bagadia, executive director at Choice Broking, said some stocks that saw fresh breakouts last Friday were still looking positive on the technical chart and recommended them for intraday trading.

Orchid Pharma recently made headlines for securing US FDA approval for a new drug

Despite an over 86 percent gain in the stock in 2023 YTD, domestic brokerage house Investec sees pharma firm Orchid Pharma (ORCD) rising another 23 percent in the next 12 months. The brokerage has initiated coverage on the stock with a ‘buy’ call and a target price of ₹ 800.

Stock market today: Orchid Pharma's share price hits new 52-week high as the drugmaker launches Qualified Institutional Placement issuance to raise capital.